Wyeth Seeks People With Becker
MD for MYO-029 Study
A trial of an experimental compound developed to treat muscular
dystrophy is seeking additional participants with Becker MD.
Becker MD is a less severe variant of Duchenne MD and results
from a partial deficiency of the muscle protein dystrophin.
MYO-029 was developed and is being tested by Wyeth Pharmaceuticals
(www.wyeth.com) of Collegeville,
Pa. It’s designed to block a natural protein called myostatin,
which limits muscle growth.
For details of criteria for entry and locations for the trial
throughout the United States, see www.clinicaltrials.gov and enter MYO-029 in the search box; or www.mda.org/research/ctrials.aspx and enter MYO-029 in the keyword box.
|
| |
|
| |
|
| |
|